Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12148860 | 1.00 | EPHX2 (0.66) | EPHX2KDM4ESLC6A5GLP1R | |
| SCHEMBL9517290 | 0.92 | GLP1R (0.61) | GLP1R | |
| SCHEMBL9441752 | 0.92 | GLP1R (0.61) | GLP1R | |
| SCHEMBL12148907 | 0.91 | EPHX2 (0.78) | EPHX2KDM4ESLC6A5 | |
| SCHEMBL12522320 | 0.91 | EPHX2 (0.63) | EPHX2SLC6A5 | |
| SCHEMBL6931475 | 0.91 | NOD1 (0.60) | GLP1R | |
| SCHEMBL13339080 | 0.88 | SLC6A5 (0.64) | EPHX2SLC6A5 | |
| SCHEMBL19195276 | 0.88 | CNR1 (0.61) | EPHX2KDM4E | |
| SCHEMBL12148863 | 0.88 | EPHX2 (0.60) | EPHX2SLC6A5 | |
| SCHEMBL1869135 | 0.88 | SLC6A5 (0.64) | EPHX2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2902013-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | Marina Biotech, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2349210-B1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20130039970-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039970-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010045512-A2 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MDRNA , INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | EPHX2 3723/4885KDM4E 4127/4885SLC6A5 602/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | EPHX2 3928/4885KDM4E 4573/4885SLC6A5 890/4885 |
| US-20130039970-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC27A1 | EPHX2 3723/4885KDM4E 4127/4885SLC6A5 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.